🏛️ Verified NIH Record • Updated 2026-07-27
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (NCT05415072)
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- Columbia University Medical Center — New York, New York
- Memorial Sloane Ketterin Cancer Ctr — New York, New York
- Novartis Investigative Site — Westmead, New South Wales
- Novartis Investigative Site — Melbourne, Victoria
- Novartis Investigative Site — Paris,
- Novartis Investigative Site — Essen,
- Novartis Investigative Site — Heidelberg,
- Novartis Investigative Site — Leiden, South Holland
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Zurich,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Uveal Melanoma
- Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma — Tampa, Florida
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — Scottsdale, Arizona
- Vorinostat in Treating Patients With Metastatic Melanoma of the Eye — New York, New York
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — Los Angeles, California
- Tebentafusp-tebn With LDT in Metastatic UM — Philadelphia, Pennsylvania
Explore by condition: All Metastatic Uveal Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.